Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | PTGFR | P43088 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27868603 | 1.00 | TBXA2R (0.50) | TBXA2RFOLH1LMNAAOC3SLC18A3 | |
| SCHEMBL6512170 | 1.00 | TBXA2R (0.50) | TBXA2RFOLH1LMNAAOC3SLC18A3 | |
| SCHEMBL8743003 | 0.93 | TBXA2R (0.58) | TBXA2RPTGER2PTGER1PTGFR | |
| SCHEMBL8742992 | 0.93 | TBXA2R (0.58) | TBXA2RPTGER2PTGER1PTGFR | |
| SCHEMBL21358345 | 0.91 | FOLH1 (0.46) | TBXA2RFOLH1AOC3 | |
| SCHEMBL641514 | 0.91 | FOLH1 (0.46) | TBXA2RFOLH1AOC3 | |
| SCHEMBL67079 | 0.87 | TBXA2R (0.58) | TBXA2RFOLH1LMNA | |
| SCHEMBL11756883 | 0.86 | FFAR1 (0.48) | TBXA2RFOLH1AOC3 | |
| SCHEMBL4311004 | 0.85 | AOC3 (0.47) | AOC3 | |
| SCHEMBL28412576 | 0.84 | NPC1 (0.41) | TBXA2RFOLH1PTGER1PTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111138276-A | Synthesis method of chiral 5- (4-fluorophenyl) -5-hydroxypentanoate | 郑州手性药物研究院有限公司 | 2020-05-12 | — | — | CN | claimed |
| CN-102605034-A | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2012-07-25 | — | — | CN | claimed |
| CN-114621299-B | Preparation method of ezetimibe intermediate | 江苏阿尔法药业股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-114621299-B | Preparation method of ezetimibe intermediate | 江苏阿尔法药业股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| CN-114621299-A | Preparation method of ezetimibe intermediate | 江苏阿尔法药业有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114621299-A | Preparation method of ezetimibe intermediate | 江苏阿尔法药业有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| CN-111138276-A | Synthesis method of chiral 5- (4-fluorophenyl) -5-hydroxypentanoate | 郑州手性药物研究院有限公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-102605034-A | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2012-07-25 | — | — | CN | disclosed |
| CN-102605034-A | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2012-07-25 | — | — | CN | disclosed |
| CN-102605034-A | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2012-07-25 | — | — | CN | disclosed |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| WO-2011073154-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| EP-0862645-B1 | STEREOSELECTIVE MICROBIAL REDUCTION PROCESS | SCHERING CORP (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-0862645-A1 | STEREOSELECTIVE MICROBIAL REDUCTION PROCESS | SCHERING CORPORATION (US) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997012053-A1 | STEREOSELECTIVE MICROBIAL REDUCTION PROCESS | SCHERING CORPORATION (US) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | TBXA2R 66/4885FOLH1 676/4885LMNA 4656/4885 |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | TBXA2R 75/4885FOLH1 777/4885LMNA 4671/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | TBXA2R 66/4885FOLH1 676/4885LMNA 4656/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | TBXA2R 66/4885FOLH1 676/4885LMNA 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.